The 1st generation of cell therapies uses DNA-based vectors including plasmids and lentivirus, and has demonstrated its efficiency. However, it also raises some questions regarding biosafety, cost, and compatibility with high throughput production. Now, the messenger RNA approach can avoid the genome integration, is safer and can ensure low immune response. So, why not use mRNA for cell therapies?
